Psychedelic treatments in Europe vary widely depending on the country, the legal issues, and the drug used. This article explores the different types of treatments that are legally available and provides resources organised by country.
A person seeking psychedelic treatment in Europe might spend an afternoon in a psychiatrist’s office, several hours in a private infusion clinic, days in a residential psychiatric facility, or months moving through screening and follow-up for a clinical trial.
These experiences may all fall under the broad label of “psychedelic treatment,” but they are not interchangeable. The medication used is only one part of the picture. Where treatment takes place, who can access it, how it is paid for, how long it takes, and what happens before and after a dosing session depend heavily on the treatment format and the country.
As of September 2026, PsyAccess lists 487 verified listings of psychedelic treatment in Europe. One route to legally accessing psychedelic or psychedelic-adjacent treatment is through an authorised ketamine or esketamine clinic. Another way is participation in a clinical trial. Certain drugs such as psilocybin are only available in a trial setting because they are not approved in the European Union.
Understanding those different settings and regulations can make the search for treatment less confusing. PsyAccess has a country-by-country directory of psychedelic medicine access that can help patients find the appropriate care for their diagnosis, location, and budget. The most common settings for psychedelic treatment include:
The Public Hospital or Health-System Clinic
Psychedelic treatment in Europe can look surprisingly similar to traditional psychiatric care in a clinic or outpatient department. One example is esketamine nasal spray, prescribed under the brand name Spravato. The European Medicines Agency approves this medication for combined treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitor (SNRI), which are more traditional, long-term antidepressants.
Spravato may help patients with treatment-resistant depression who have not responded to at least two different antidepressant treatments during the current moderate-to-severe depressive episode, and is used in combination with an SSRI or SNRI.
During treatment with Spravato, patients self-administer the nasal spray in a clinic or clinician’s office under the care of a healthcare professional. Because esketamine can elevate blood pressure, blood pressure is monitored before dosing and reassessed after administration, typically at around 40 minutes and thereafter as clinically indicated. Patients can leave the office or outpatient setting when the clinician decides their vital signs and mental state are stable enough for discharge home.
Normally, esketamine requires more than one treatment to achieve its full effect. According to the European dosing recommendations, the drug is administered twice a week for 4 weeks. If the symptoms improve after this course of treatment, the dosage is usually decreased to once weekly for another 4 weeks. Esketamine can be continued as maintenance treatment after the depressive symptoms are controlled, and treatment may occur once every 1 or 2 weeks.
At the Istituto di Neuroscienze in Italy, Prof. Stefano Pallanti’s team provides intranasal esketamine and, when clinically appropriate, intravenous ketamine. A prospective patient first undergoes a brief telephone screening to determine whether the medication is appropriate or helpful. The team then reviews the patient’s medical records and referral documents and completes a medical assessment.
On the day of treatment, patients undergo another brief clinical assessment, including an interview and standard rating scales, to assess the severity of their condition before treatment. A typical visit takes approximately 2.5 to 4 hours and includes medical assessment, treatment, monitoring, and recovery. When ketamine is combined with another treatment, such as transcranial magnetic stimulation (TMS), the session may take longer. Patients are cared for by a team of psychiatrists, specialised nurses, clinical psychologists or psychotherapists, and anaesthesiologists for intravenous ketamine.
The physical and interpersonal setting can meaningfully influence the subjective treatment experience, particularly feelings of safety, anxiety and willingness to engage with difficult material. Pallanti’s team says patients frequently appreciate the clinic’s “friendly, comfortable, and welcoming atmosphere”, which is intentionally different from a conventional hospital environment. When researching a treatment centre, it is important to select a location with the appropriate staff, surroundings, prior assessments, and experience.
Treatment costs vary by location and health system. For example, esketamine is reimbursed in much of continental Europe, although eligibility criteria, clinic requirements, prior treatment requirements, and reimbursement processes vary widely. Prospective patients can research these differences through PsyAccess’s country access and reimbursement guides.
For example, Germany has approved esketamine, and patients can obtain it at many public and university psychiatric centres. The medication is reimbursed in Germany’s public health system for treatment-resistant depression. The PsyAccess Spravato directory can help patients understand requirements and legality of esketamine in different countries. As of August 2026, PsyAccess lists 212 verified Spravato centres in 15 countries, with large networks in Poland, Switzerland, the Netherlands, Germany, and Italy.
This type of treatment may be less appropriate for someone looking specifically for psilocybin or another classic psychedelic, or for someone who expects therapy to take place simply during the dosing session. Psychological support varies between centres and should be confirmed directly with the provider.
An Office-Based Psychiatric Practice
In some countries, specialist psychiatric practices provide psychedelic treatment in a smaller outpatient setting. Some patients appreciate the more intimate setting and the follow-up care with the same healthcare professional. For example, Germany has allowed statutory health insurance to reimburse Spravato for eligible patients with treatment-resistant depression in qualifying office-based psychiatric practices since 2023.
Patients usually start by contacting the psychiatric practice or being referred by another clinician. The psychiatrist reviews the diagnosis, previous treatments, current medications, medical history, and whether the patient meets the treatment and reimbursement requirements.
Treatment monitoring is still an important part of office-based treatment. Clinicians still administer esketamine under medical supervision, with close assessment in these settings.
Offices that provide esketamine may or may not provide psychotherapy as part of the treatment plan. Some locations focus on medication administration and monitoring, while others offer psychological integration surrounding the session or separately. Some practices also take over maintenance treatment that was initially started in the hospital.
Office-based care may suit patients who meet criteria for esketamine but prefer a smaller outpatient setting and can travel to repeated appointments. It may not suit someone who needs inpatient psychiatric care, overnight monitoring, or a highly structured psychotherapy program surrounding each dosing session.
A Private Ketamine Clinic
Ketamine is a medication that is related to esketamine, but it isn’t the same thing. It is usually administered through an IV, and it is generally prescribed off-label for depression. For this reason, the way in which ketamine is administered in private clinics varies.
Some clinics provide a medically monitored infusion of ketamine, and others perform ketamine-assisted psychotherapy. When psychotherapy is used alongside the medication, a professional therapist or psychologist helps the patient integrate and process the experience.
Clínica Synaptica in Barcelona offers an example of ketamine-assisted psychotherapy. According to clinic director Òscar Parés, prospective patients first undergo an in-depth clinical interview with medical director Dr Joan Obiols, a psychiatrist. If treatment is appropriate, the patient is assigned a therapist and attends a 90-minute preparation session before the first ketamine treatment. The therapist discusses expectations and establishes a therapeutic relationship with the patient. The patient and therapist then agree on a treatment framework and discuss ways to manage difficult experiences throughout treatment.
On the day of treatment, the therapist will briefly check in with the patient about how they are feeling. A medical professional then administers ketamine while the patient rests in a reclining chair or bed with the therapist present. Most patients choose to wear an eye mask and listen to a preselected therapeutic playlist.
A psychologist remains in the room for the entire infusion, and an attending doctor is also present at the clinic. As the medication's effects subside, the session transitions into an initial integration period. Additional psychotherapy sessions without ketamine are scheduled a few days after treatment.
Overall, an appointment for intravenous ketamine lasts approximately 2 hours and 45 minutes. The patient may receive 1 or 2 sessions per week for several weeks, up to 8 ketamine sessions interspersed with integration sessions. Parés estimates that a standard program amounts to approximately 25 to 30 hours of direct multidisciplinary care.
Clìnica Synaptica is a private service, and patients primarily pay for treatment out of pocket. According to Parés, its standard complete protocol costs around €3,455. Some patients with private insurance policies that reimburse external medical visits may be able to recover a portion of the expense.
Parés also notes that the process is more involved than some patients realise. Some patients arrive expecting ketamine to behave like a “magic bullet”. What surprises them, Parés says, is “how active, demanding, and participatory the process actually is”.
In this model of care, ketamine is one part of the treatment plan. Preparation, emotional engagement, psychotherapy, and integration are used alongside ketamine to help patients understand the experience and translate any therapeutic gains into ongoing psychological or behavioural change.
At Eulas Clinics in Scotland, medical records are reviewed first, followed by an assessment with the unit manager and then a separate psychiatric assessment. Registered manager Sean Gillen says the service primarily treats adults with treatment-resistant depression, including patients who also have post-traumatic stress disorder, anxiety, obsessive-compulsive disorder, or addictions. Most patients are based in Scotland, although the clinic accepts patients from elsewhere.
Eulas Clinics is also self-funded. Gillen says patients receive full pricing information before treatment in the clinic’s service pack. Because the program includes psychiatric assessment, preparation, intravenous ketamine sessions, integration, psychotherapy, and longer-term psychological follow-up, patients should compare the cost of the complete program rather than the price of an individual infusion.
At Eulas, assessments and psychotherapy appointments last approximately 1 hour, while dosing visits last about 2.5 hours. The intravenous ketamine infusion itself lasts approximately 45 minutes. According to Gillen, the broader treatment program lasts around 8 months when preparation, dosing, psychotherapy, and long-term follow-up are included.
Before the first dose, Eulas patients complete 4 preparation psychotherapy sessions. Integration takes place the day after each ketamine session, psychotherapy continues for several weeks after dosing has finished, and psychology-assistant appointments continue twice monthly for 6 months after completion of treatment. The clinical team includes consultant psychiatrists, anaesthetists, nurses, psychotherapists, psychology assistants, and the unit manager.
Gillen also frames suitability in less medical terms. He says prospective patients should ask themselves whether they are ready to change, willing to put effort into change, and whether remaining as they are feels more frightening than the work involved in getting better.
Ketamine-assisted psychotherapy may especially appeal to someone who wants preparation and integration explicitly built around the dosing sessions. Clínica Synaptica excludes patients on several medical and psychiatric safety grounds, including a history of psychosis, uncontrolled hypertension, certain vascular or intracranial conditions, pregnancy, and other contraindications identified during psychiatric and medical assessment. Individual clinics may use different criteria. Patients who are unable to fund private treatment, cannot attend repeated appointments, or need a higher level of inpatient psychiatric support may need a different route.
Prospective patients can browse verified ketamine and ketamine-assisted psychotherapy providers on the PsyAccess KAP directory.
A Residential Inpatient Program
Some psychiatric facilities provide psychedelic treatment as part of an inpatient or residential treatment program. In this setting, medication may be only one component of an interdisciplinary, comprehensive treatment plan. Treatment may also include psychiatric assessment, nursing care, psychotherapy, and other therapeutic modalities.
Residential programs may be more practical for patients who cannot arrange transport home after sessions several times per week. Furthermore, patients may also benefit from other activities such as art therapy, group work, physical activity, meals, and therapeutic settings.
These treatment programs are more intensive and can offer a higher level of support and supervision. However, they also require a greater time commitment and may be more expensive than other types of treatment.
Notably, regulated residential psychiatric treatment programs are not the same as psychedelic ceremonies (such as ayahuasca ceremonies). Medication is highly regulated, staff are qualified and well-trained, and evidence-based treatments are preferred in formal treatment programs. Medical inpatient treatment often operates within a healthcare system, with formal assessments, professional oversight, and protocols for patient safety. Patients considering this form of treatment should ask what happens between medication sessions, how psychiatric or medical emergencies are handled, and what follow-up care is available.
An inpatient psychiatric program may be particularly relevant when the person requires broader psychiatric care in addition to ketamine. Drawbacks include cost, travel, time away from home, and the program's intensity. Someone who needs only a medically supervised outpatient treatment may find a residential model unnecessarily burdensome.
A Clinical Trial
Many psychedelic drugs such as MDMA, LSD, or psilocybin are not approved and are only available in clinical trials. For example, psilocybin treatment is available only in research settings and through a small number of exceptional access pathways in certain countries. PsyAccess currently lists 129 verified clinical-trial sites across 19 countries in Europe.
The participant experience in a clinical trial differs greatly from that in a clinic. First, one must qualify through strict eligibility criteria. The study may test the drug only on patients with a certain diagnosis, severity level, or treatment history. People with certain medical conditions, age, previous treatments, psychiatric history, concurrent medications, or other parameters may be excluded from the trial. Screening often involves several interviews, examinations, laboratory testing, and detailed review of medical records.
Second, the study design may not be what most people expect. Some psychedelic studies are open label, meaning that the participants know what they are receiving. In a randomised clinical trial, participants are assigned to different groups that may receive different doses of medication, treatment modalities such as psychotherapy, or no medication at all. In each randomised clinical trial, participants may be part of a control group rather than a treatment group. Patients in the control group receive a placebo, a lower dose of the investigational drug, treatment as usual or a comparator drug, not the actual medication. These types of programs may require a heavy time commitment, psychological assessments, and follow-up visits for weeks or months.
Clinical trials do not charge participants for the investigational treatment or study procedures. Travel expenses are also commonly reimbursed, although the exact policy varies by study.
What are clinical trials like for patients?
A published account from one of Imperial College London’s early psilocybin studies describes the patient experience:
Kirk Rutter, then 45, joined a study of psilocybin for treatment-resistant depression after struggling with depression following his mother’s death. He had never taken psilocybin before and was nervous about what the experience might be like.
Rutter later told Imperial College London that the research team explained the study and guided him through the process beforehand. By the time he received psilocybin, he said he felt much more relaxed, helped by the staff, the treatment room's layout, and calming music.
However, Rutter described going through periods of “psychedelic turbulence” during both dosing sessions. His account is useful precisely because it does not reduce psychedelic research to receiving a drug and waiting to see whether it works. Preparation mattered. The room mattered. Music mattered. Having people available to guide him mattered. So did the fact that parts of the experience were difficult.
Those details echo what providers working with ketamine describe in ordinary clinical care: the medication may be central to the session, but the experience surrounding it can shape what treatment feels like.
For someone who qualifies, a trial can provide access to an investigational treatment that is otherwise unavailable, but it comes with several hurdles.
Switzerland: An Unusual Path to Psychedelic Care
Switzerland is different from other countries in Europe because certain patients can receive the classic psychedelics through an individual medical authorisation pathway. Under this program, a clinician can seek an authorisation based on exceptional circumstances, including the lack of an equivalent alternative treatment or severe, incurable disease where the patient’s suffering may be alleviated by the treatment. These patients can receive substances that are normally not approved if their condition justifies it.
This type of treatment may include psilocybin, lysergic acid diethylamide (LSD) and methylenedioxymethamphetamine (MDMA or ecstasy). Around 100 clinicians treated 723 patients through the program in 2024. Depressive disorders were the most common indication overall. In 2024, psilocybin was most frequently authorised for depressive disorders, while MDMA was used for several conditions including depressive disorders and PTSD. Treatment is generally self-funded and may involve long waiting lists at experienced practices.
However, obtaining this exception may be difficult. The authorisation is specific to the doctor and patient, and treatment is part of a course rather than a one-dose psychedelic session. Patients typically receive 2 to 4 sessions within 12 months.
Switzerland also offers more conventional treatment options such as ketamine and esketamine at 52 designated centres. Private off-label ketamine is available too, and clinical trials are also an option.
Read the PsyAccess guide to legal psychedelic treatment in Switzerland
Germany: Psilocybin and Compassionate Use
Germany also has another pathway to psilocybin treatment. Since July 2025, adults with treatment-resistant depression have been able to receive psilocybin through an authori00277-9/abstract)s00277-9/abstract)ed compassionate-use program00277-9/abstract) at 2 sites: the Central Institute of Mental Health in Mannheim and OVID Clinics Berlin.
However, eligibility is restricted to those with depression who have not responded to at least 2 trials of antidepressant medication and are not able to participate in a clinical trial. Treatment capacity is also very limited, with approximately 50 patients anticipated in the first year, and is explicitly not equivalent to the regulatory approval of psilocybin.
Read the PsyAccess guide to psilocybin access in Germany
How to Choose the Best Treatment Setting
The most important first step is to determine which treatment options are available. The following are important questions to ask:
What am I eligible for?
Esketamine, ketamine, ketamine-assisted psychotherapy, a psychedelic clinical trial, and exceptional-access programs all have different criteria and entry requirements. These requirements depend on the diagnosis, prior treatments, medications, psychiatric history, location, physical health, and payer availability. You can check which legal PsyAccess routes may fit your circumstances.
What exactly am I paying for?
Look at the total treatment cost, not just the cost of the medication. Important questions to ask include whether the fee includes the initial medical assessment, medication session, monitoring, psychotherapy, preparation, integration, and follow-up. If reimbursement is an option, ask whether approval is needed before treatment and which parts are covered.
What happens on treatment day?
The experience can vary widely across treatment centres. Find out if the treatment is performed in a hospital room or private space. Ask who monitors the treatment session and what the setting is like (eye masks, music, privacy, etc.). Find out how long you need to remain at the facility after monitoring treatment and whether you will need a support person to take you home.
What happens before and after the medication?
This may be one of the biggest differences between the treatment models. At some clinics, preparation and integration are built into the program, and the patient’s psychologist stays in the room during the dosing session. At another service, the emphasis may be on medication administration and monitoring, with psychotherapy at another facility or none at all.
How much of a commitment can I realistically make?
An important aspect of psychedelic treatment is the time involved. Determine whether repeated outpatient appointments, an inpatient stay, or long-term monitoring are required. Visit frequency may matter more for locations that are far away and require more travel.
The Setting is Part of the Treatment Experience
One of the most important parts of psychedelic treatment is “set and setting.” These treatments can temporarily increase emotional sensitivity, change perception and cause psychological vulnerability. For this reason, regulated programmes pay close attention to the physical environment, therapeutic relationship, preparation and availability of trained support. Music, lighting and other aspects of the setting may be incorporated differently depending on the treatment protocol.
Anxiety, fear and psychological difficulty can occasionally be a part of psychedelic treatment, but these challenges may sometimes become clinically meaningful when processed with appropriate support, but distress should not be viewed as therapeutic in itself. Therefore, prospective patients should understand beforehand how the treatment team manages psychological or medical difficulties during a session.
Patients who are unsure where to begin can browse PsyAccess by country, review its detailed access and reimbursement guides, or use the eligibility check to narrow down which legal pathways may fit their circumstances.
Frequently asked questions
Which psychedelic treatments are actually legal in Europe right now?
Esketamine and ketamine are approved for medical use in most countries right now. Switzerland has a limited medical use program of LSD, MDMA, and psilocybin. Germany has a compassionate use program for psilocybin.
Can I get MDMA-assisted therapy for PTSD in Europe?
MDMA is not an approved medicine for PTSD across Europe. You may be able to access MDMA-assisted therapy for PTSD as part of research programs or a clinical trial in certain countries, such as Switzerland.
What's the difference between a psychedelic retreat and legal psychedelic treatment?
The difference between a psychedelic retreat and a legal psychedelic treatment has to do with medical regulation, safety precautions, and legal status. While treatments take place in strict clinical settings within medical/legal frameworks, retreats focus more on wellness and may be led by facilitators with varying qualifications.
Do I have to stop my antidepressants before psychedelic treatment?
It depends on the antidepressant and the psychedelic treatment. Certain medications can interact with psychedelics and should be stopped. Other antidepressants are safe to continue taking. You should discuss your medications with your treatment team prior to making any changes.
Does health insurance cover ketamine or esketamine treatment?
Coverage varies substantially by country and healthcare system. Esketamine treatment has regulatory approval for treatment-resistant depression, but reimbursement depends on national eligibility and funding rules. Off-label ketamine is less consistently reimbursed and is frequently self-funded.
How do I find and join a psychedelic clinical trial in Europe?
The best way to find an active trial is through public clinical registries. You can filter these by location, substance, and health condition. The EU Clinical Trials Register or ClinicalTrials.gov is a good place to start.